Technical Analysis for GLYC - GlycoMimetics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Wide Bands | Range Expansion | -12.95% | |
| Wide Bands | Range Expansion | -20.52% | |
| MACD Bearish Signal Line Cross | Bearish | -20.67% | |
| Wide Bands | Range Expansion | -20.67% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | -17.38% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -17.38% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| Down 10% | about 21 hours ago |
| Down 1 ATR | about 21 hours ago |
| Gapped Down (Full) | about 22 hours ago |
| Down 5% | about 22 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/01/2024
GlycoMimetics, Inc. Description
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Drug Discovery Acute Myeloid Leukemia Chemotherapy Clinical Trial Product Testing Hematologic Cancers Pseudomonas Sickle Cell Disease Nursing Research
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.5299 |
| 52 Week Low | 0.1406 |
| Average Volume | 24,774,172 |
| 200-Day Moving Average | 0.97 |
| 50-Day Moving Average | 0.24 |
| 20-Day Moving Average | 0.37 |
| 10-Day Moving Average | 0.40 |
| Average True Range | 0.05 |
| RSI (14) | 49.75 |
| ADX | 39.38 |
| +DI | 31.23 |
| -DI | 25.55 |
| Chandelier Exit (Long, 3 ATRs) | 0.48 |
| Chandelier Exit (Short, 3 ATRs) | 0.31 |
| Upper Bollinger Bands | 0.55 |
| Lower Bollinger Band | 0.19 |
| Percent B (%b) | 0.39 |
| BandWidth | 96.03 |
| MACD Line | 0.04 |
| MACD Signal Line | 0.05 |
| MACD Histogram | -0.011 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.42 | ||||
| Resistance 3 (R3) | 0.42 | 0.40 | 0.40 | ||
| Resistance 2 (R2) | 0.40 | 0.37 | 0.39 | 0.40 | |
| Resistance 1 (R1) | 0.36 | 0.36 | 0.35 | 0.36 | 0.39 |
| Pivot Point | 0.34 | 0.34 | 0.33 | 0.33 | 0.34 |
| Support 1 (S1) | 0.30 | 0.31 | 0.29 | 0.30 | 0.27 |
| Support 2 (S2) | 0.28 | 0.30 | 0.28 | 0.26 | |
| Support 3 (S3) | 0.25 | 0.28 | 0.26 | ||
| Support 4 (S4) | 0.24 |
